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Abstract
The Expected Value of Perfect Partial Information (EVPPI) is a decision-
theoretic measure of the “cost” of parametric uncertainty in decision mak-
ing used principally in health economic decision making. Despite this
decision-theoretic grounding, the uptake of EVPPI calculations in practice
has been slow. This is in part due to the prohibitive computational time
required to estimate the EVPPI via Monte Carlo simulations. However,
recent developments have demonstrated that the EVPPI can be estimated
by non-parametric regression methods, which have significantly decreased
the computation time required to approximate the EVPPI. Under certain
circumstances, high-dimensional Gaussian Process regression is suggested,
but this can still be prohibitively expensive. Applying fast computation
methods developed in spatial statistics using Integrated Nested Laplace
Approximations (INLA) and projecting from a high-dimensional into a
low-dimensional input space allows us to decrease the computation time
for fitting these high-dimensional Gaussian Processes, often substantially.
We demonstrate that the EVPPI calculated using our method for Gaus-
sian Process regression is in line with the standard Gaussian Process re-
gression method and that despite the apparent methodological complexity
of this new method, R functions are available in the package BCEA to im-
plement it simply and efficiently.
1 Introduction
Broadly speaking, the objective of publicly funded health care systems, such as
the UK National Health Service, is to maximise health gains across the general
population, given finite monetary resources and limited budget. Bodies such as
the National Institute for Health and Care Excellence (NICE) in the UK pro-
vide guidance on decision-making on the basis of health economic evaluation.
This covers a suite of analytic approaches for combining costs and clinical con-
sequences of an intervention, in comparison to alternative options which may
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already be available, with the aim of aiding decision-making associated with
health resources. Much of the recent research has been oriented towards build-
ing the health economic evaluation on sound and advanced statistical decision-
theoretic foundations, arguably making it a branch of applied statistics [1, 2]
and increasingly often under a Bayesian approach [3, 4, 5, 6].
In a nutshell, the process involves the identification of suitable measures of
clinical benefits (generically termed as “effectiveness”) and costs associated with
an intervention, which we indicate as (e, c). The variable c usually includes the
cost of acquisition and implementation of the health intervention (e.g. a drug),
or societal costs such as those related to number of days off work or social
care. As for the clinical benefits e, they can be a “hard” measurement (e.g.
number of cases averted), but most often are considered in terms of Quality
Adjusted Life Years (QALYs) [7], combining the quantity and the quality of life
provided by a given intervention. Individual level variability in the outcome is
expressed in terms of a joint probability distribution p(e, c | θ), indexed by a
set of parameters θ whose uncertainty is described by a probability distribution
p(θ), in a Bayesian context.
According to the precepts of decision theory [8], for each intervention t =
0, . . . , T (t = 0 being the “reference” alternative, e.g. standard of care and t =
1, . . . , T the new options being evaluated) the health economic outcomes (e, c)
are combined in order to quantify the overall “value” of the intervention, usually
in terms of the monetary net benefit which is given by the costs associated with
the treatments subtracted from rescaled effectiveness (we define this formally in
§2). The alternative associated with the highest expected net benefit is deemed
as “the most cost-effective”, given current evidence — notice that in a Bayesian
context, this expectation is taken over the distributions of both the individual
level outcomes and population level parameters. From the decision-theoretic
point of view, the identification of the overall expected net benefit is all that
is needed to reach the optimal decision given the current state of knowledge
available to the decision-maker [9, 10].
However, the implementation of a health care intervention is usually associ-
ated with risks such as the irreversibility of investments [11]. Moreover, health
economic models often involve a relatively large number of parameters, usually
estimated using limited information. For these reasons, health technology as-
sessment (HTA) bodies such as NICE recommend a thorough investigation of
the impact of uncertainty on the decision making process of parametric and
model uncertainty, a process known in the health economics literature as Prob-
abilistic Sensitivity Analysis (PSA) [12, 13, 14, 15].
The analysis of the value of information (VoI) [16] is an increasingly popular
method to conduct PSA in health economic evaluations [17, 18, 11, 19, 20, 21, 1,
22]. The basic idea of VoI analysis is to compare the decision based on current
evidence to the one that would be made, had the uncertainty in the parameters
been resolved e.g. by observing an (infinitely) large amount of data.
The main advantage of the analysis of the VoI is that it directly addresses the
potential implications of current uncertainty, not only in terms of the likelihood
of modifying the current decision in light of new and more definitive evidence,
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but also in terms of the opportunity cost of the incorrect decision. If this
cost is low, there is little value in agonising about the decision, even for a
low probability of cost-effectiveness, as the implicit penalty is negligible if the
decision turns to be wrong in the face of new evidence. Therefore, the probability
of cost-effectiveness alone can dramatically overstate or down-play the decision
sensitivity. For this reason, it has been advocated that VoI measures should
also be presented when representing decision uncertainty [17, 6, 23, 24].
Despite the useful features of a VoI analysis, its uptake in health economic
evaluation has been slow. VoI analysis has been hindered by several different
factors, both theoretical and practical. Theoretically, issues such as whether
the economic model can be trusted and what constitutes a “high” level of de-
cision uncertainty given that VoI measures are unbounded. Practically, VoI
measurements can be computationally costly unless restrictive assumptions are
made [25]. It is typically easy to calculate numerically (but not analytically) the
expected value of learning all the model parameters perfectly. This is known
as the (overall) Expected Value of Perfect Information (EVPI). However, this
quantity has often little practical use, as it will be rarely possible to learn all the
model parameters at once in a new study. Thus, the decision-maker is usually
interested in the expected value of information about subsets of parameters of
interest, sometimes called focal parameters. This will indicate which parameters
are driving decision uncertainty, and thus where future research may add value.
This subset analysis is concerned with the computation of the Expected Value
of Perfect Partial Information (EVPPI) and is usually computationally costly.
In the last few years, research has focused on alternative methods that could
be used to speed up the estimation of the EVPPI without compromising its accu-
racy, so as to increase its applicability in health economic evaluations [26, 27, 28].
A review of these methods is given in [29]. A promising development [30] has re-
cently explored the use of non-parametric regression methods, specifically Gen-
eralised Additive Models (GAMs) [31] and Gaussian Process (GP) regression
[32], to approximate the EVPPI. These methods have been shown to be very
effective: GAMs are very flexible and extremely inexpensive in computational
terms if the number of parameters of interest P is relatively small (e.g. P < 5).
When P is large, however, GAMs either overfit or simply cannot be used as
the number of parameters exceeds the number of data points. GP regression
methods may be used as an alternative regression method: on the one hand,
they overcome the limitations of GAMs and can be used to estimate the EVPPI
for higher dimensions of the subset of parameters of interest, producing a signif-
icant improvement over simpler, but computationally prohibitive methods. On
the other hand, however, the computational cost to fit a GP regression model to
a realistic problem including a relatively large number of parameters can still be
substantial. Moreover, as EVPPI values may need to be calculated for a large
number of different parameter sets, this computational time can be multiplied
10- or 100-fold.
To overcome this issue, we propose in this paper a faster method to fit GP
regression, based on spatial statistics and Bayesian inference using Integrated
Nested Laplace Approximation [33]. We translate the estimation of the EVPPI
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into a “spatial” problem by considering that the simulated net benefit values,
i.e. the values from the PSA, are “observed” at different points in the pa-
rameter space. We can therefore use the available technology for fast Bayesian
computation of spatial models [34, 35] to approximate the EVPPI efficiently.
Furthermore, as this spatial machinery loses its computational advantages in
higher dimensional spaces, we demonstrate that the use of dimension-reduction
techniques to project onto a 2-dimensional space is accurate for the examples
considered. Thus, we can use this method along with dimensionality reduction
to approximate the EVPPI quickly and efficiently in applied cases, irrespective
of the complexity of the problem.
The paper is structured as follows: in §2 we present the general framework
used for the analysis of the value of information in health economic evaluation
and in §2.1 we briefly review the main characteristics of GPs and specifically
their application in the computation of the EVPPI. Then in §3 we present our
proposal for a new method to compute the EVPPI; first we briefly review the
main features of the spatial statistics literature based on stochastic partial dif-
ferential equations (described in §3.1), which is used to estimate the correlation
function required to fit the GP. Then, in §3.2 we discuss how this can be brought
to bear in the modelling and efficient computation of the EVPPI. In §4 we test
our method in comparison to existing GP regression models to estimate the
EVPPI on a set of health economic examples. We particularly focus on the
issues of computational time as well as accuracy of the estimation. Finally, in
§5 and §6 we present some technical aspects as well as the main conclusions
from our work.
2 Value of information analysis in health eco-
nomics
PSA is usually based on a simulation approach [36, 6, 37]: uncertainty about the
relevant parameters θ is described by a suitable probability distribution, from
which a sample of S values is obtained, e.g. via Monte Carlo (MC) sampling
from the prior or Markov Chain MC (MCMC) estimation of the posteriors under
a Bayesian framework, or using bootstrap in a frequentist approach. First, for
each intervention, the expected value is computed conditionally on each value of
the simulated parameters. Assuming the commonly used monetary net benefit
[38] to quantify the value of the different treatments, this value is estimated by
NBt(θs) = kE[e | θs; t]− E[c | θs; t],
where θs is the s-th set of simulated values for the parameters vector, e and c
are the measures of effectiveness and cost respectively and k is the willingness
to pay, which is used to put the cost and effectiveness measures on the same
scale, i.e. in terms of the amount of money that the decision maker is willing to
pay to increment the benefits by one unit. Notice here that (e, c) represent the
individual level effectiveness and costs for a specific value of θ and conditional
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on any observed data. Therefore, the expectation is taken over the joint distri-
bution of (e, c) to give the population level net benefit for the specific value of
θ.
The vector of values NBt = [NBt(θ1), . . . ,NBt(θS)]
′
is a sample from the
distribution of the decisions (randomness being induced by uncertainty in the
parameters) and can be analysed to determine the impact of parameter uncer-
tainty on the decision-making process. If the optimal decision, i.e. the inter-
vention with the maximum expected net benefit, varies substantially across the
simulations, then the decision-making process is sensitive to the uncertainty in
the model parameters and more research could be recommended by the HTA
bodies.
For example, consider a non life-threatening infectious disease (such as mild
influenza) and assume that under current practice (t = 0), individuals have a
risk of infection pi. If they become infected, they are subject to an average
duration of the disease of λ days, for each of which they have to follow a course
of treatment that costs γ monetary units (say, £). The new treatment, whose
cost-effectiveness is being assessed (t = 1), has an average implementation cost
of £ξ and it is assumed that the chance of infection is reduced by a factor ρ.
However, if an individual becomes infected then they will still have a period of λ
days in which they will require treatment at the cost of £γ per day. Under these
(unrealistically!) simple assumptions, we can define θ = (pi, λ, γ, ξ, ρ). Assuming
further that suitable probability distributions can be associated with each of the
elements of θ to describe our current uncertainty, we could reasonably define
the net benefits for the two interventions as
NB0(θ) = k(−piλ)− piγλ and NB1(θ) = k(−piρλ)− (ξ + piργλ),
implying that the clinical benefit is given by minus the chance of being infected
multiplied by the length of the infection and that cost is given by the sum of
the implementation cost of the intervention and the overall cost of treatment if
infected.
In general terms, the expected opportunity loss of making a decision based
on current evidence instead of on perfect information can be quantified by the
Expected Value of Perfect Information, defined as
EVPI = Eθ
[
max
t
NBt (θ)
]
−max
t
Eθ [NBt (θ)] , (1)
where the expectation is taken with respect to the posterior distribution of θ.
Since these expectations are typically not analytically available, they are
estimated through simulations. Provided the number S of simulations used to
perform PSA is large enough to characterise the underlying distribution of the
decisions, it is straightforward to compute a MC estimate using the simulated
values for the net benefits
ÊVPI =
1
S
S∑
s=1
max
t
NBt(θs)−max
t
1
S
S∑
s=1
NBt(θs),
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which usually requires almost no extra computational time, once the PSA sam-
ples are available.
In most practical situations, however, the interest is in quantifying the value
of reducing uncertainty on a specific subset φ ⊂ θ of parameters of interest as
it may be feasible to conduct a specific clinical trial or literature review in order
to potentially reduce the level of current uncertainty in these parameters. For
example, for the simple model described above we may be interested in learning
the value of investigating the epidemiological parameters φ = (pi, λ, ρ) describing
the risk and duration of the infection and the effectiveness of the intervention in
reducing it, while considering the remaining parameters ψ = (γ, ξ) as nuisance.
This value is known as the Expected Value of Perfect Partial Information
and in the general setting is defined as
EVPPI = Eφ
[
max
t
Eψ|φ [NBt(φ,ψ)]
]
−max
t
Eθ [NBt(φ,ψ)] , (2)
where θ = (φ,ψ). The last term in equation (2) is again the maximum expected
net benefit under current evidence. The first term is made by two nested el-
ements: the inner part is the maximum expected net benefit that would be
obtained if uncertainty in the parameters of interest only were resolved. This
means that the inner expectation assumes that the value of φ is known. Of
course, as the “true” value of φ is not known, it is necessary to consider the
expectation over the current distribution of φ.
In simple cases, where the conditional expectation Eψ|φ [NBt(φ,ψ)] is avail-
able analytically as a function of φ, then it is possible to calculate the EVPPI
using a single sample from p(φ). This can occur in several settings, the most
common of which is known as the “sum-product” form for the net benefit. This
allows us to calculate the EVPPI based on samples that have already been
obtained for PSA as part of a standard health economic analysis.
A more general solution, which involves additional sampling, is to use a
nested MC scheme, in which first a sample φ1, . . . ,φSφ is obtained from the
marginal distribution of φ and then, for each s = 1, . . . , Sφ, a sampleψ1, . . . ,ψSψ
from the conditional distribution p(ψ | φs) is also simulated. This produces a
total of Sφ × Sψ simulations, where both numbers need to be large in order
to reduce the Monte Carlo error such that the EVPPI estimates are suitably
precise; for example, Brennan et al. [39] suggest that Sφ and Sψ should be in the
order of 10 000, although this may need to be higher in complex models. This
immense computational burden and the difficulty in deriving analytic results
in practical scenarios have been arguably the main reasons for the relatively
limited practical use of the EVPPI as a tool for PSA [40, 41].
2.1 Gaussian Process regression for efficient computation
of the EVPPI
Gaussian Processes are a family of stochastic processes used in statistics and
machine learning for non-parametric regression, classification and prediction [32,
42] and can be thought of as an extension of the multivariate Normal distribution
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to an infinite vector of observations [43, 32]. Strictly speaking, a GP is an
infinite collection of random variables, any subset of which follows a multivariate
Gaussian distribution [44]. A GP is entirely defined in terms of its mean and
covariance functions [45, 46], which calculate the mean vector and covariance
matrix for each subset of random variables depending on some input values and
a small set of hyperparameters. These inputs determine the specific mean and
variance for each random variable in the process. Consequently, GPs can be
used for regressing random variables on a set of input values.
To fit a GP for non-parametric regression, the general form of the mean and
covariance function is specified by the modeller. In general, the covariance func-
tion is a taken as a decreasing function of the “distance” between any two input
values, i.e. points that are “closer” have a higher correlation [32, 47] where
“distance” and “closeness” can be measured in different ways depending on the
context. These functions typically depend on a set of hyperparameters; for
example, the covariance function is often defined in terms of a smoothness pa-
rameter that determines the similarity between two points “close” together and
a GP marginal variance parameter. Once these general functions are specified,
problem-specific values for the hyperparameters need to be determined.
In a Bayesian setting, vague and conjugate priors have been proposed for
the hyperparameters allowing for partially analytically tractable posterior dis-
tributions [30, 48]. Integration and numerical optimisation can then be used to
find maximum a posteriori estimates of the GP parameters. Therefore, GPs are
an increasingly popular method of regression since their extreme flexibility typ-
ically is obtained at a relatively small computational cost as MCMC methods
may be avoided to fit them. However, for large datasets the cost of fitting a GP
is still substantial as numerical optimisation in this setting requires inverting an
S × S dense matrix, at a computational cost of O(S3).
The basic idea exploited by Strong et al. [30] is to consider the net benefit of
each treatment t computed using the s−th set of simulated values of the param-
eters as a noisy observation of the “true” underlying conditional expectation
NBt(θs) = Eψ|φs [NBt(θ)] + εs, (3)
with εs
iid∼ Normal(0, σ2ε) and assuming conditional independence between the
net benefits under the different treatments t. As the conditional expectation on
the right hand side changes as a function of the parameters of interest only, we
can equivalently write (3) as
NBt(θs) = gt(φs) + εs. (4)
Once the functions gt(·) have been estimated using GP regression methods, the
fitted values gˆt(φs) can be used to approximate the EVPPI by computing
̂EVPPI = 1
S
S∑
s=1
max
t
gˆt(φs)−max
t
1
S
S∑
s=1
gˆt(φs).
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Assuming a GP structure for the functions gt(·) in a linear regression frame-
work effectively amounts to modelling
gt(φ1)
gt(φ2)
...
gt(φS)
 ∼ Normal(Hβ,Σ), (5)
where: φs is the s-th simulated value for φ; H is a design matrix
H =

1 φ11 · · · φ1P
1 φ21 · · · φ2P
...
. . .
1 φS1 · · · φSP
 ; (6)
β is the vector of regression coefficients describing the linear relationship be-
tween the parameters of interest φ and the conditional expectation of the net
benefits; and the covariance matrix Σ is determined by the covariance function
C, a matrix operator whose elements C(r, s) describe the covariance between
any two points gt(φr) and gt(φs).
Strong et al. [30] use a squared exponential, also known as an exponentiated
quadratic, covariance function CExp, defined by
CExp(r, s) = σ2 exp
[
−
P∑
p=1
(
φrp − φsp
δp
)2]
(7)
where φrp and φsp are the r-th and the s-th simulated value of the p-th parameter
in φ, respectively. For this covariance function, σ2 is the GP marginal variance
and δp defines the smoothness of the relationship between two values that are
“close together” in dimension p. For high values of δp the correlation between
the two conditional expectations with similar values for φp is small. The δp
values are also treated as hyperparameters to be estimated from the data.
Combining equations (4) and (5), we can directly model the “observed”
vector of net benefits as
NBt(θ1)
NBt(θ2)
...
NBt(θS)
 ∼ Normal(Hβ,CExp + σ2εI). (8)
The model in (8) includes 2P + 3 hyperparameters: the P + 1 regression coeffi-
cients β, the P smoothness parameters δ = (δ1, . . . , δP ), the marginal variance
of the GP σ2 and the residual error σ2ε , also known as “nugget variance”. In
this setting, therefore, the PSA samples for φ are the “covariates” used to fit
the non-parametric regression model, while the “response” is represented by
the net benefits. Given that the estimation of the hyperparameters is the most
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expensive component of fitting a GP [30], in computational terms the efficiency
of this method to estimate the EVPPI depends on the number of parameters of
interest.
Strong et al. [30] integrate out β and σ analytically and use numerical opti-
misation to calculate the posterior mode of the other hyperparameters δ and σε
analytically. This allows for great flexibility but at a computational cost in the
order of S3. As PSA is usually based on relatively large number of simulated
values from the posterior distributions of θ (i.e. in the thousands) this proce-
dure still takes considerable computational effort despite producing a significant
improvement over MC methods, especially for larger numbers of parameter of
interest.
3 Fast computation of the EVPPI using Inte-
grated Nested Laplace Approximation
3.1 Spatial statistics and Stochastic Partial Differential
Equations
An interesting application of GP regression is in the field of spatial statistics,
where measurements are taken at different points in a spatial domain. For
example, these can be the cases of influenza at locations in a geographical area
(e.g. a country) or the level of pollution at different monitoring sites. The main
assumption in spatial statistics is that points that are “closer” to each other in a
geographical sense share more common features and are influenced by common
factors than those “further away” [49].
A very popular specification of a spatial model when exact locations are
available is based on the Mate´rn family of covariance functions [50], defined by
CM(r, s) = σ
2
Γ(ν)2ν−1
(κ‖φr − φs‖)νKν(κ‖φr − φs‖),
where ξ = (σ, κ, ν) is a vector of hyperparameters, ‖.‖ denotes the Euclidean
distance and Kν is the modified Bessel function of the second kind and order
ν. The Mate´rn covariance function is related to the covariance function in (7),
which can be obtained when δp is constant for all p = 1, . . . , P and ν → ∞
[32]. This implies that the resulting covariance matrix for a specific set of input
values is still dense, i.e. a large number of the matrix elements are non-zero,
which in turn generates a computational cost for matrix inversion in the order
of S3.
However, Lindgren et al. [51] demonstrate that a sparse matrix can be used
to approximate a GP with a Mate´rn covariance function (Mate´rn GP) by using
Stochastic Partial Differential Equations (SPDE), which in general leads to a
computation time for matrix inversion in the order of S
3
2 . It can be shown that,
in addition to being defined in terms of a relationship with the multivariate
Gaussian, a Mate´rn GP is also exactly equal to the function gt(φ) that solves a
specific SPDE of the form
9
τ(κ2 −∆)α2 gt(φ) =W(φ),
whereW is Gaussian noise, ∆ is the Laplacian operator, α = ν+ P2 (with P = 2,
in the spatial context) and the marginal variance of the Mate´rn GP is
σ2 =
Γ(ν)
Γ(α)(4pi)
P
2
κ−2ντ−2.
Therefore, finding the solution to this SPDE is exactly equivalent to finding the
function gt(φ), which as mentioned in §2.1 is instrumental in estimating the
EVPPI.
The fundamental implication of this result is that efficient algorithms for
solving SPDEs can be used to approximate the Mate´rn GP. In practice, the
SPDE is solved using the finite element method [52]. First, the region over
which the SPDE is being solved, i.e. the range of φ, is split into small areas.
In the proper spatial 2-dimensional case, a grid of small triangles is used; an
example of this triangulation relating to the amount of rainfall in Switzerland
over a pre-specified time horizon is shown in Figure 1. Notice that there are
Figure 1: An example of the grid approximation used to approximate the Mate´rn
GP in a proper spatial problem. The thick black line represent the border of
Switzerland. The blue dots represent the positions where data points have been
observed. These data points are used to estimate the value of the Mate´rn GP
throughout the geographical space (i.e. the whole area covered by Switzerland,
in this case).
two triangulation boundaries with the border of Switzerland added for clarity.
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An inner boundary encases (or “hugs”) all the data points relatively tightly,
while the outer boundary is further from the points. This is because boundary
conditions are imposed on the SPDE solver and it is important to avoid these
impacting on the estimation of the smooth function gt(·). The value of the
Mate´rn GP is then approximated by simple (linear) functions within each small
triangular area. Therefore, the triangles are more tightly packed within the
inner boundary to give a good approximation to the Mate´rn GP, while in the
outer region the grid can be rougher as the approximation is not as important.
The Mate´rn GP is directly approximated at each intersection where triangles
meet (i.e. the vertices). Then, within each triangle it is approximated using
linear interpolation by taking a weighted sum of the weights at the three corners
of the triangle. Therefore, the vertex weights ω, which are estimated from the
data (i.e. the net benefit values, in this case), entirely determine the value of the
Mate´rn GP. Lindgren et al. [51] demonstrate that these vertex weights can be
assumed to have a multivariate Gaussian distribution with a specific precision
matrix, conditional on κ and τ . This precision matrix is, to a very good degree
of approximation, sparse as non-zero entries correspond loosely only with points
that “share a triangle”.
3.2 Computing the EVPPI using SPDE-INLA
Assuming a Mate´rn covariance function, the model in (8) becomes NBt ∼
Normal(Hβ,CM + σ2εI), which can be equivalently re-expressed as
NBt ∼ Normal(Hβ + F (ω), σ2εI), (9)
where ω = (ω1, . . . , ωS)
′ ∼ Normal (0,Q−1(τ, κ)) are the vertex weights and
Q(τ, κ) is the sparse precision matrix determined by the SPDE solution. The
function F (·) maps from the position of the ω values to the position of the data
points on the grid. As is possible to see in Figure 1, many of the points do not lie
exactly on the intersections between the triangles and are therefore calculated
as a function of several ω values.
Interestingly, the specification in (9) is in fact a Latent Gaussian Model [53]
as the response of interest NBt is dependent on a latent Gaussian vector ω
controlled by a small number of hyperparameters (κ and τ). This means that
inference can be performed in a very efficient way by using the Integrated Nested
Laplace Approximation (INLA) algorithm [53] (cf. Apprendix A), programmed
in the R package R-INLA [54], which also includes extensions to implement the
SPDE method [51, 34, 55, 56, 57, 58].
The SPDE-INLA method has been developed and successfully applied in a
spatial context [57, 59, 60], where inputs are proper coordinates (i.e. longitude
and latitude, hence defined in a 2-dimensional space) which makes the GP
approximation extremely fast. However, calculating the EVPPI relies on a set of
much higher dimensional inputs. While in theory the SPDE machinery works in
higher dimensional spaces, the computational advantages will diminish in these
cases.
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To fully exploit the computational savings of the SPDE-INLA procedure,
we re-express the problem of computing the EVPPI in a “spatial” context. In
this case, the simulated parameter vector for φ designates a point in the P -
dimensional parameter space. We consider that the net benefit, calculated as
a function of φ, has been “observed” at this point. We then wish to find a
representation of these P -dimensional points in at most 2-dimensional space,
so that we can efficiently estimate the Mate´rn covariance of this representation
using the SPDE-INLA methodology. If no such projection exists then the com-
putational complexity of fitting a Mate´rn GP with a high dimensional SPDE
means that the standard GP method is more appropriate.
As this projection will be used to predict the net benefit values, it makes
sense to use a regression-based dimension reduction method. This class of meth-
ods tries to find a sufficient reduction, i.e. one for which the projection contains
the relevant information about the net benefit function. Formally, we can ex-
press this condition as NBt ⊥⊥ φ | R(φ), where R(·) is the reduction function
from P , the length of φ, to d, the number of dimensions needed to capture all
the information in φ. There is a wealth of methods that can be used to esti-
mate this sufficient reduction [61, 62, 63, 64, 65, 66]. Specifically, we focus on
Principal Fitted Components [65, 66] to calculate the EVPPI.
3.2.1 Principal Fitted Components
Principal Fitted Components (PFC) is a model based inverse regression method.
This means that in order to find a sufficient reduction we consider a model for φ
as a function of NBt. As different models can be specified and lead to different
sufficient reductions, the best fit model amongst a set of candidates should be
chosen before finding the sufficient reduction.
The general form of these PFC models is based on a linear structure
φ = µ + Υf(NBt) + ,
where µ is the intercept; Υ is a P × d matrix to be estimated to determine the
sufficient reduction; f(·) is a vector-valued function of NBt; and  is an error
term in the exponential family. The form of the error structure changes the
way in which the reduction is calculated and methods have been developed for
independent, heteroskedastic and unstructured errors.
In order to use PFC, the function f(·) and the error structure need to
be specified. In our problem, we consider normally distributed errors and set
f (NBt) =
[
α1NBt, α2NB
2
t , . . . , αhNB
h
t
]T
, although in general f(·) can map
to any function of NBt. Additionally, the number of dimensions d needed to
capture all the relevant information in φ needs to be specified. It is then advis-
able to select the values of d and h (the polynomial degree) associated with the
best performing inverse regression specification, e.g. in terms of model fitting,
as measured by information criteria such as the AIC [66].
The cost of fitting any of these models individually is negligible and thus
fitting a number of models in correspondence to a set of chosen d and h values
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adds very little to the computational time required to estimate the EVPPI.
In any case, because PFC assumes that the number of dimensions needed to
capture the information in φ is no larger that then number of dimensions in
the function f(·), for simple relationships between the net benefit and φ, the
sufficient regression is low dimensional.
To fully exploit the spatial nature of the SPDE-INLA methodology, d must
be set to 2. However, identifying the optimal value for d allows us to check the
validity of the EVPPI approximation. If one dimension is sufficient to capture all
the information in φ, there is no harm in using a second component because this
will only add information and the reduction will remain sufficient. On the other
hand, using two dimensions when the AIC suggests d > 2, may lead to a loss
in information. Consequently, the EVPPI estimate based on a two-dimensional
reduction of φ may be biased. In light of the large computational savings and
the fact that the AIC has a tendency to overestimate d [66], it may still be
worth using the projection to estimate the EVPPI and then perform thorough
model checking (e.g. by means of the residual plots) to assess its performance,
before resorting to more computationally intensive methods. We return to this
point in §4.
From the theoretical point of view, PFC provides a robust method for de-
termining the sufficient reduction [66]. Thus, combining PFC and SPDE-INLA
to estimate the EVPPI seems to be a valid strategy. Additionally, due to the
flexibility of the INLA algorithm it is possible to cater for more complicated
structures in the relationships between the net benefit and the parameters of
interest, as we discuss in §5.
We have combined PFC and SPDE-INLA, along with some simple PFC
model selection, in the R package BCEA [67, 68] to allow users to integrate stan-
dard economic analysis with efficient calculations for the EVPPI in large dimen-
sions. This function relies on the R-INLA and ldr packages [54, 69]. We have
also implemented model checking procedures for the non-parametric regression
as standard in order to aid practitioners. This potentially improves the use
of value of information analysis as a tool for PSA in applied health economic
problems.
4 Examples
We present two case studies of health economic models and compare the esti-
mates of the EVPPI using the direct GP regression implemented by Strong et
al. and our SPDE-INLA projection method. For both case studies, random
subsets of between 5 and 16 parameters of interest were considered to com-
pare the performance of the GP procedures — notice that this represents the
standard range of parameter subsets that would be used practically for EVPPI
calculation using GP [30, 70]. For each subset, the EVPPI was calculated using
both methods and for a willingness-to-pay threshold of k = 20000 monetary
units, say £. The computational time and EVPPI estimate was then recorded
for both methods to allow a direct comparison.
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4.1 Vaccine Study
The first case study (referred to as the “Vaccine study”) is a Bayesian health-
economic model proposed to analyse the effect of an influenza vaccine on health
outcomes and costs. A more detailed description of the example is presented
in [6]. The parameters are sampled from their joint posterior distribution us-
ing Markov Chain Monte Carlo (MCMC) methods. These sampled parameter
values are used to calculate the net benefits and the EVPPI.
Two treatment options are considered, either the vaccine is available to the
population (t = 1) or not (t = 0). If an individual gets influenza, they are
treated with anti-viral drugs and will often visit the doctor. Complications may
occur, including pneumonia and hospitalisation, in which case there will be some
indirect costs such as time off work. The cost of the treatment is the acquisition
cost of the drugs, the time in hospital, the doctor’s visits and the cost of the
vaccine. The benefit of the treatment is measured in QALYs, to which each
adverse effect contributes negatively.
The Vaccine model includes 28 key parameters representing the probability
of infection, the reduction in risk due to the vaccine, the occurrence of com-
plications, the monetary costs of the interventions and the QALY loss due to
different health states. However, as the model is built as an evidence synthesis,
additional sources of uncertainty are present; for instance, the true number of
people getting influenza or the true number of people getting side effects are
unknown. Considering all the unobserved quantities in the model, the number
of parameters increases to 62.
4.2 SAVI Study
The second case study is a simple fictional decision tree model with correlated
parameters, presented at the Sheffield Accelerated Value of Information web
app [71] (hence this example is referred to as the “SAVI study”). The model
has two treatment options and 19 underlying parameters. A more in-depth
model description is presented in [39]. Most importantly, the 19 underlying
parameters are assumed to follow a multivariate Gaussian distribution and thus
the conditional distribution p(ψ | φ) can be computed analytically and the
EVPPI can therefore be calculated using MC simulation. The SAVI web app
provides 10 000 PSA samples of all the 19 parameters, along with the simulated
costs and benefits of both treatment options. The number of available PSA
samples poses a significant challenge for the standard GP regression method.
For this reason, only the first 1 000 observations are used for the comparison
with our SPDE-INLA method.
4.3 Computational Time
We begin our discussion of the two EVPPI estimation methods by comparing the
computational time required to obtain an estimate. The EVPPI estimates were
calculated using 1 000 PSA samples for both case studies and both methods.
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To compare our SPDE-INLA method we used the code available from Strong
[72] with a slight modification. This modification changed the numerical opti-
miser (used to estimate the hyperparameters) to give quicker computation time
and more accurate results although in some cases this optimiser can struggle
numerically and the slower optimiser must be used.
Additionally, to allow for a fair comparison between the two methods only
500 PSA runs were used to estimate the hyperparameters by numerical optimi-
sation. This is because for each step, an S × S dense matrix must be inverted.
As this is computationally expensive, it is suggested [30] that the full PSA run
is not used to calculate the hyperparameters. Once the hyperparameters have
been estimated, all 1 000 PSA samples are used to find the fitted values gˆt(φs),
so all the information is utilised. Using all 1 000 observations for the optimi-
sation step can give more accurate results and is sometimes necessary (see for
example §4.4).
Table 1: The computational time required (in seconds) to calculate an EVPPI
using both the GP regression method and SPDE-INLA method for increasing
numbers of parameters for both case studies
Number of parameters Computation time (seconds)
of interest Vaccine Example SAVI Example
GP SPDE-INLA GP SPDE-INLA
5 17 9 17 7
6 42 10 14 7
7 45 10 18 7
8 57 11 21 8
9 74 8 26 8
10 86 8 31 9
11 70 7 37 8
12 60 8 47 8
13 84 11 52 7
14 188 8 66 6
15 470 7 70 7
16 121 8 71 7
The computational time for the GP regression increases substantially with
the number of parameters of interest, between 17 and 470 seconds for the Vaccine
case study and 17 and 71 seconds for the SAVI example. However, interestingly,
the computation time does not increase uniformly for GP regression. This is
due to the numerical optimisation, as occasionally additional steps are required
to reach convergence.
The computation time for our SPDE-INLA method remains constant as the
number of parameters increases. The computation time of our SPDE-INLA
method is significantly lower than the GP regression method, up to around 70
times faster. Even for 5 parameters of interest, it is between 2 and 2.5 times
faster, despite the fact that we are using all the data points to estimate the
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EVPPI, albeit from a projected input space.
To understand if our method scales to larger PSA datasets, EVPPI estimates
using all 10 000 PSA samples from the SAVI case study were also calculated.
The computational time required to calculate an EVPPI estimate was between
40 and 80 seconds with an average time of 56 seconds. This is significant as
the computation time does not increase exponentially using the SPDE-INLA
method; the computation time is between than 6 and 10 times slower for a 10
fold increase in number of PSA samples. Crucially, the speed of our SPDE-INLA
method depends on the density of the grid approximation. Therefore, its com-
putational effort could be decreased by using a sparser grid, although this would
clearly affect the quality of the EVPPI estimate. It would, therefore, be possible
to use our method to calculate the EVPPI for larger PSA data sets. This may
be relevant, for instance, in models involving individual level simulations (often
referred to as “microsimulations” in the health economic literature) [73], where
larger PSA samples are required to fully assess the underlying distributions.
4.4 Accuracy
In general, it is difficult to establish whether an estimate of the EVPPI is accu-
rate since the calculations of the EVPPI are frequently analytically intractable.
In fact, for the Vaccine model there is no closed-form expression for the EVPPI,
while, given its simplified model structure, for the SAVI example long MC runs
can establish the EVPPI up to an inconsequently small Monte Carlo error.
Thus, it is difficult to determine which method is more accurate when the two
approximate EVPPI values diverge, as no baseline comparator is easily avail-
able. Nevertheless, there are at least two potential features that we can use to
assess the reliability of our estimates.
4.4.1 Monotonicity with respect to the number of parameters of
interest
It can be easily shown that the EVPPI is a non-decreasing function of the
number of parameters of interest (cfr. a proof in appendix B). This means that,
provided the smaller subsets are entirely contained within the larger subsets, the
EVPPI estimates should be non-decreasing. This property provides a possible
assessment of the accuracy of the methods: if one method fulfils this property
and the other does not, then the former could be more accurate. It is important
to note that monotonicity is only a necessary condition for a good EVPPI esti-
mate and not a sufficient one. It is clearly possibly to construct a function that
gives a monotone sequence, such as simply giving the number of parameters in
the set, but clearly does not estimate the EVPPI at all.
Figure 2 shows the EVPPI estimate for increasing parameter subset sizes for
both case studies. The smaller sets of parameters of interest are simply subsets
of the larger sets of parameters. For the Vaccine example, shown in panel (a),
the standard GP regression method has some difficulty retrieving monotonicity,
specifically for the parameter set containing 10 parameters which is clearly over-
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estimated. Our SPDE-INLA method also overestimates the EVPPI for the set
containing 10 parameters, but by 0.01 or less than 1%. This given an indication
of the accuracy of our EVPPI estimation method. This over-estimation for the
standard GP method is due in part to the incorrect estimation of the hyperpa-
rameters based on the reduced PSA dataset. If the estimate is obtained using
all 1 000 PSA samples then the EVPPI is 1.39, which respects monotonicity but
the computation time increases to 256 seconds compared to 86.
For the SAVI example (panel b) the monotonicity is respected across both
methods and the EVPPI values, rounded to 3 significant figures, are similar.
For both examples, the EVPPI values for the smaller parameter subsets are
similar across both methods. As the length of φ increases the SPDE-INLA
method underestimates slightly compared to the standard GP but only by at
most 3% of the total EVPPI value. There is evidence that the SPDE-INLA
method is accurate while possibly guarding against spurious results that come
from estimating the hyperparameters based on a smaller subset of the PSA
samples. We note however that some issues with underestimation may occur
with larger subsets.
4.4.2 SPDE-INLA as EVPI approximation
To investigate whether the SPDE-INLA method underestimates the EVPPI
for larger parameter subsets, we compare the results from our method to the
overall EVPI, which represents the largest parameter subset available for each
example. As mentioned earlier, the overall EVPI (1) can be easily calculated
directly from the available PSA data, since as there are no nuisance parameters
we can use a single loop to estimate it. We can then use our method to calculate
the overall EVPI, by considering that all the underlying model parameters are
of interest. This allows us to compare our method directly with the “true”
MC EVPI estimate. The EVPI was calculated for both cases studies and the
results are shown in Table 2. The computational time required to calculate
these estimates is 14 seconds for the Vaccine example and 8 seconds for the
SAVI.
Table 2: The EVPI values calculated using the PSA samples directly and our
SPDE-INLA method
Case Study MC EVPI SPDE-INLA EVPI
Vaccine 2.52 2.51
SAVI 2100 2080
For both case studies, the SPDE-INLA approximation is correct to two sig-
nificant figures, with a small discrepancy in the third significant figure. This
gives a further indication that the EVPPI estimated using our method is an
accurate method for calculating the EVPPI, possibly demonstrating that even
for large numbers of parameters of interest the underestimation of the EVPPI
is not severe.
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For the Vaccine example, there are 62 parameters that contribute to the
model uncertainty. We are therefore approximating the Mate´rn covariance func-
tion with a projection from a 62- to a 2-dimensional space. However, despite
the difficulty of preserving the original data structure with this projection, the
AIC suggests that this is a sufficient reduction and the EVPI estimate is still
very close to the true value.
4.4.3 Analytic Results
Since the parameters for the SAVI case study are in fact drawn from a known
multivariate Normal distribution, the EVPPI can be calculated using a single
MC loop. The parameters of interest, φ, are sampled from their posterior
marginal and then the conditional expectation for each simulated parameter
vector is calculated analytically. Strong et al. [30] provide these EVPPI values,
based on a long MC run, for three different parameters subsets of size 2 and 4,
which can be used to test the accuracy of our procedure.
Both GP regression and GAM can be used to calculate the EVPPI using
all 10 000 avalible PSA samples and the willingness-to-pay is fixed at £10 000.
Table 3 gives the single MC loop EVPPI together with all three estimated
values, GAM, GP regression and SPDE-INLA. It is clear from this table that
our method’s performance is in line with the other approximation methods while
all 3 methods overestimate the true EVPPI value in this setting.
Table 3: Comparison of the EVPPI estimation methods, standard GP, GAM
regression and the SPDE-INLA method with “true” EVPPI values based on 107
Monte Carlo simulations.
EVPPI estimate (Time to compute in seconds)
Parameter Subset MC Simulations GP GAM SPDE-INLA
2 Parameters - φ5, φ14 248 274 (375) 277 (0.78) 278 (41)
4 Parameters - φ5, φ6, φ14, φ15 841 861 (367) 862 (98) 856 (48)
2 Parameters - φ7, φ16 536 549 (390) 546 (0.25) 549 (43)
The computational time required to calculate these estimates are given in
Table 3. Clearly, for the 2 parameter setting the GAM regression method is
the most appropriate as it takes under a second to calculate the EVPPI esti-
mate. However, for the 4 parameter example, the computational time is lowest
for our SPDE-INLA method, which takes half the computational effort of the
GAM regression method and around 10% of the standard GP. This demon-
strates the computational effort required for the standard GP method using a
large number of PSA samples, despite using only 500 PSA samples to find the
hyperparameters (see §4.3).
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5 Technical Considerations
There are several technical aspects relating to the implementation of this method
that can affect its estimation performance. These considerations are mostly due
to ensuring that the approximations used to estimate the EVPPI are not too
rough, whilst retaining the computational advantages of the method.
The most important technical aspect of the SPDE-INLA procedure is the
grid approximation used to build up the Finite Element Approximation to the
Mate´rn field. To create an accurate approximation, the triangulation must com-
pletely surround the data points with a significant distance from the outermost
data point to the final boundary, as there are artificial constraints at the bound-
ary of the triangulation. To reduce the computation time, a tight boundary hugs
the data points closely and within this boundary the mesh points are dense to
give a good approximation. Outside of this inner boundary, the approximation
can be rougher and the triangles are therefore larger. The mesh approxima-
tion is most efficient when the two dimensions (coming from the projections
for EVPPI calculation) are on approximately the same scale. Therefore, the
PSA inputs should be rescaled before calculating the projection. This avoids
situations such as that shown in Figure 3 (a), where a large number of triangles
cover an area with no observations. Rescaling has no effect on the estimated
EVPPI value [30] but does significantly decrease that computation time.
The triangulation must be dense enough to adequately capture the underly-
ing structure or the EVPPI estimate will be incorrect. However, as the compu-
tation time of the method is directly related to the number of vertices, there is
a trade-off between accuracy and computational time. Most importantly, larger
datasets require denser triangulations to calculate the EVPPI efficiently and
typically the number of mesh points should be greater than the number of data
points. If some estimation difficulties are observed by a standard model check-
ing procedure, such as residual plots, the estimation can sometimes be improved
by making the triangulation more dense.
The inner boundary should completely encase the data points. However,
sometimes extreme outliers can be isolated by this boundary and this affects
the Mate´rn field approximation. Therefore, care must be taken to ensure that
all points lie within the inner boundary. However, as our “data”, φ, are typ-
ically from PSA samples (such as MCMC samples), a relatively large number
of observations are normally available and thus outliers are rare. An extreme
outlier should probably be investigated thoroughly.
In some more complex examples, both estimation methods can struggle and
therefore the small loss in flexibility from our method can slightly worsen its
estimation performance. However, this drawback can be overcome by adding
additional structure to the linear predictor. This means that the H matrix in
Equation (6) changes its form to include non-linear functions of the parameters.
Mostly importantly, allowing for 2nd or 3rd order interactions between the pa-
rameters seems to account for the flexibility lost by using the projections whist
retaining the computational advantages. Adding these extra terms fits easily
into the INLA framework and so this can been easily added to the standard
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EVPPI calculation method.
Finally, we reiterate that model checking should be thoroughly performed
to ascertain when this additional flexibility should be used. Specifically, highly
structured residuals indicate that the regression curve has not picked up all
the relevant relationships present in the data [74, 30]. Therefore, we advocate
integrating model checking as a standard part of EVPPI estimation and stress
that poorly fitted models result from either a lack of flexibility in the linear
predictor or an incorrect PFC model.
Our implementation of the INLA-SPDE method to compute the EVPPI in
the R package BCEA accounts for all these potential issues, including allowing
the user to customise the linear predictor, and thus provides a reliable tool for
practitioners. Options are also available to fine tune the model used to find the
PFC and to use standard residual plots to check the fit of the non-parametric
regression model [67].
6 Conclusion
This paper develops a fast method for Gaussian Process regression in order
to reduce the computational effort required to calculate the EVPPI for health
economic evaluations. This method is based on a spatial interpretation of GP
regression and projections into 2-dimensional space. This in turn allows us to
use a fast computation method developed in spatial statistics, based on calcu-
lating a sparse precision matrix that approximates a Mate´rn GP. Finally, this
sparse precision matrix allows us to use the INLA methodology for fast Bayesian
computation of the hyperparameters for the GP. It also allows us to find fitted
values at no additional cost, which are then in turn used to estimate the EVPPI.
Despite the methodological complexity of our GP regression method, the
user-friendly R package R-INLA can be used to estimate the hyperparameters
and find the fitted values. This simplifies the implementation of our method,
allowing us to integrate it into a straightforward R function. This GP regression
method significantly decreases the computation time required to calculate the
EVPPI for larger subsets of parameters of interest as it is at least 2 times faster
than standard GP regression method, taking around 10 seconds to calculate an
EVPPI estimate with 1 000 PSA samples.
There is little loss of accuracy when using our method in the examples we
have considered. For larger subsets the EVPPI estimate is slightly underes-
timated compared to the standard GP methods, but this does not seem to be
severe as the EVPI estimates are very close. Additionally, in some examples, our
method seemed to be more accurate than the standard GP regression method,
due to the breakdown of numerical optimisation. These results are conditional
on the dimension reduction being sufficient to capture all the information in φ.
There are several important points of further research. Firstly, further work
is required to understand the impact of our new method on the bias and standard
error of the EVPPI estimate, especially considering the error introduced by using
projections. These properties are important and estimation methods have been
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provided for the standard GP regression method [30]. Secondly, a sparser grid
could decrease the computational time required for this method. However, a
comprehensive understanding of the impact of the density of the grid on the
EVPPI estimate is needed. Ideally, we would determine an optimal grid density
in terms of required computation time and accuracy. Finally, it is important to
investigate how successful our method is compared to other fast GP regression
methods. Lindgren et al. [51] demonstrate that the SPDE framework can be
extended to non-stationary fields and thus, this method may provide quick GP
regression for non-stationary processes.
Our method has the potential to have an important impact on the practice
of health economic evaluation; the analysis of the value of information is well
known as a potentially effective tool to determine research priority and the
accuracy of decisions made as a result of economic models. Nevertheless, their
practical applications has been thwarted by the complexity of the resulting
calculations. Our method substantially reduces the computational time and is
implemented in an R package, with stand-alone code also available from the
authors, which means that practitioners and regulators can use it routinely to
assess the impact of uncertainty in models on the decision-making process being
investigated.
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A The Integrated Nested Laplace Approxima-
tion
The Integrated Nested Laplace Approximation (INLA) is a fast approximate
Bayesian inference method for a wide class of models known as Latent Gaussian
Models (LGMs) [53]. This class of models is broad as many standard modelling
scenarios can be reformulated as LGMs including regression models, dynamic
models and spatio-temporal models [53].
A LGM is characterised by the fact that the data, yi can be defined by a
parametric family with a parameter µi linked to a structured linear predictor
ηi, based on a set of covariates γi = (γi1, . . . , γiJ , . . . , γi(J+K)), through some
link function h(·):
h(µi) = ηi = α+
J∑
j=1
fj(γij) +
K∑
k=1
βkγik + i, (10)
where fj(·) are unknown functions of the covariates γi, β = (β1, . . . , βK) are
fixed regression coefficients, i is some error term, and J andK are the number of
functions of covariates and regressed covariates in the model [75]. The functions
fj can be of any form and typically can represent autoregressive models, spatial
effects or seasonal effects. In these settings the covariates γi give sequential or
spatial information about the data yi. A standard generalised linear model also
fits this framework where all the functions fj(·) are equal to 0.
To complete the LGM formulation, a Gaussian prior is assigned to the set
of parameters defining the linear predictor θ = (α,β, fj(·), i), depending on
some hyperparameters λ (typically, these determine the precision matrix of θ).
Clearly, the number of elements in θ is likely to be large and therefore, to
allow for fast computation, INLA is restricted to the case where the Gaussian
prior used has a “sparse” precision matrix. This Gaussian prior with a sparse
precision matrix is also known as a Gaussian Markov Random Field (GMRF)
[76]. Fast computation using INLA is ensured if λ contains a relatively small
number of elements, typically no greater than 6.
At first glance, enforcing sparsity in the prior for θ may seem restrictive
as sparsity in the covariance matrix implies marginal independence. However,
sparsity in a precision matrix only enforces conditional independence, a much
looser restriction. A 0 entry in the precision matrix implies that the two ele-
ments are independent conditionally on all other elements. The Markov prop-
erty encoded in this sparse matrix implies that the field is memoryless: values
only depend directly on a few neighbours. In the SPDE-INLA setting these
neighbours are those ω values which share a triangle.
Operationally, INLA explores the approximate joint posterior of the hyper-
parameters λ by determining the density of the Laplace approximation at a grid
of points in the support of λ. This grid is found by “stepping” along each axis
of the hyperparameter space until the density falls below a specified threshold.
The density of the Laplace approximation is then evaluated at each combination
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of these axis points; if the density at these points is above the threshold then
the point is included in the grid. Interpolation is then used to approximate the
posterior at all points in λ. The posterior marginals for λ can then be found
by using these lattice points for numerical integration.
The marginals for the parameters θ are then approximated by another (sim-
plified) Laplace approximation. This Laplace approximation is evaluated at each
of the hyperparameter values on the lattice and the approximate marginals for θ
are given as a weighted sum of the Laplace approximation for each configuration
of the hyperparameter set (weighted by the density at that point). In this sense,
the approximate marginals for θ are nested within the Laplace approximation
for posterior distribution of the hyperparameters.
B Monotonic EVPPI estimates
It can be easily demonstrated that the EVPPI is a non-decreasing function of the
size of the parameter subset, provided the smaller subset is entirely contained
within the larger subset. Firstly, some notation must be set up. In line with the
paper, θ represents the set of all underlying model parameters, φ is the full set
of parameters of interest and ψ is the complement set, θ = (ψ,φ). In addition
to this notation, define ξ ⊂ φ as a smaller subset of parameters of interest and
ξc as the complement of this set such that φ = (ξ, ξc).
Using this notation we demonstrate that
EVPPI(φ) ≥ EVPPI(ξ),
where EVPPI(φ) is the EVPPI of the parameter subset φ, as follows:
EVPPI(φ) = Eφ
[
max
t
Eψ|φ [NBt(θ)]
]
−max
t
Eθ [NBt(θ)]
= Eξ
[
Eξc|ξ
[
max
t
Eψ|φ [NBt(θ)]
]]
−max
t
Eθ [NBt(θ)]
≥ Eξ
[
max
t
Eξc|ξ
[
Eψ|φ [NBt(θ)]
]]−max
t
Eθ [NBt(θ)]
Eξ
[
max
t
Eξc|ξ
[
Eψ|(ξ,ξc) [NBt(θ)]
]]−max
t
Eθ [NBt(θ)]
= Eξ
[
max
t
E(ψ,ξc)|ξ [NBt(θ)]
]
−max
t
Eθ [NBt(θ)] = EVPPI(ξ)
by Jensen’s inequality as the function max(·) is convex.
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Figure 2: The EVPPI estimate for the Gaussian Process regression method (GP)
and the new method developed in this paper (SPDE) for increasing parameter
subset size for the Vaccine (panel a) and the SAVI (panel b) case studies.
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(a) (b)
Figure 3: Two grid approximations for the same data set. The LHS shows
the triangulation when the variables are left on their original scale, with the
projected data points in blue. Notice that there are a large number of triangles
in this case, but a relatively small number that surround the data points. In
contrast to this, on the right, where the data points are scaled we note that a
much larger number of mesh points cover the data, allowing for a more accurate
Mate´rn field approximation for a fixed computational time.
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